{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-25-000040","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.898295+00:00","generated_at":"2026-05-17T19:42:08.051992+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mirum Q2 revenue $127.8M; raises FY 2025 guidance to $490-510M","bullets":["Q2 global net product sales $127.8M, up 64% YoY from $77.9M.","LIVMARLI sales $88.2M (+87% YoY); Bile Acid Medicines $39.6M (+30%).","FY 2025 revenue guidance raised to $490-510M from prior range.","Cash $321.7M; volixibat VISTAS topline expected Q2 2026.","MRM-3379 Phase 2 in Fragile X expected Q4 2025 initiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-25-000040","json":"https://secwatch.observer/filing/0001759425-25-000040.json","markdown":"https://secwatch.observer/filing/0001759425-25-000040.md","text":"https://secwatch.observer/filing/0001759425-25-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942525000040/0001759425-25-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942525000040/mirm-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:42:08.051992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}